Omeros - 16 Year Stock Price History | OMER
Historical daily share price chart and data for Omeros since 2009 adjusted for splits and dividends. The latest closing stock price for Omeros as of July 07, 2025 is 3.08.
- The all-time high Omeros stock closing price was 26.69 on September 04, 2018.
- The Omeros 52-week high stock price is 13.60, which is 341.6% above the current share price.
- The Omeros 52-week low stock price is 2.95, which is 4.2% below the current share price.
- The average Omeros stock price for the last 52 weeks is 6.21.
| Omeros Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2025 | 6.7522 | 9.8400 | 11.2100 | 2.9700 | 3.0800 | -68.83% |
| 2024 | 4.6401 | 3.2900 | 12.1500 | 2.8800 | 9.8800 | 202.14% |
| 2023 | 3.8862 | 2.4800 | 7.5700 | 1.0800 | 3.2700 | 44.69% |
| 2022 | 4.2523 | 6.9900 | 7.4600 | 1.7500 | 2.2600 | -64.85% |
| 2021 | 14.5458 | 14.5200 | 23.5300 | 5.6700 | 6.4300 | -54.99% |
| 2020 | 13.3243 | 13.6150 | 21.3200 | 9.0300 | 14.2850 | 1.38% |
| 2019 | 16.0534 | 11.8500 | 20.5600 | 11.6500 | 14.0900 | 26.48% |
| 2018 | 16.9450 | 20.1550 | 26.6900 | 9.0000 | 11.1400 | -42.67% |
| 2017 | 17.1065 | 10.1000 | 26.5800 | 8.9500 | 19.4300 | 95.87% |
| 2016 | 11.5152 | 14.7900 | 16.3700 | 7.3400 | 9.9200 | -36.94% |
| 2015 | 18.3820 | 25.0100 | 26.3500 | 10.9000 | 15.7300 | -36.52% |
| 2014 | 14.3080 | 12.0600 | 24.7800 | 9.9400 | 24.7800 | 119.49% |
| 2013 | 6.4532 | 5.3900 | 13.2300 | 3.7600 | 11.2900 | 117.53% |
| 2012 | 8.6929 | 4.0000 | 13.2500 | 3.9900 | 5.1900 | 31.39% |
| 2011 | 4.8167 | 8.5000 | 8.5000 | 3.1700 | 3.9500 | -52.06% |
| 2010 | 6.8037 | 7.2900 | 8.7700 | 5.2400 | 8.2400 | 17.38% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.188B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $233.904B | 28.13 |
| Boston Scientific (BSX) | United States | $154.336B | 38.64 |
| Stryker (SYK) | United States | $150.874B | 31.55 |
| EssilorLuxottica (ESLOY) | France | $127.819B | 0.00 |
| Medtronic (MDT) | Ireland | $113.364B | 16.07 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.609B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.066B | 26.28 |
| ResMed (RMD) | United States | $37.677B | 28.30 |
| GE HealthCare Technologies (GEHC) | United States | $34.831B | 16.54 |
| Agilent Technologies (A) | United States | $34.480B | 22.48 |
| Terumo (TRUMY) | Japan | $25.244B | 32.79 |
| Koninklijke Philips (PHG) | Netherlands | $23.274B | 16.33 |
| Insulet (PODD) | United States | $21.186B | 83.16 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.532B | 11.90 |
| Baxter (BAX) | United States | $15.914B | 11.88 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.262B | 0.00 |
| Demant (WILYY) | Denmark | $8.971B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.846B | 23.82 |
| Lantheus Holdings (LNTH) | United States | $5.564B | 14.03 |
| Prestige Consumer Healthcare (PBH) | United States | $3.952B | 17.66 |
| Perrigo (PRGO) | Ireland | $3.739B | 9.48 |
| Haemonetics (HAE) | United States | $3.693B | 16.82 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.456B | 28.72 |
| ICU Medical (ICUI) | United States | $3.333B | 24.58 |
| QuidelOrtho (QDEL) | United States | $2.042B | 14.04 |
| LeMaitre Vascular (LMAT) | United States | $1.907B | 42.62 |
| AtriCure (ATRC) | United States | $1.572B | 0.00 |
| Acuren (TIC) | United States | $1.378B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.258B | 12.77 |
| Green Thumb Industries (GTBIF) | United States | $1.164B | 26.19 |
| Neogen (NEOG) | United States | $1.157B | 14.81 |
| Phibro Animal Health (PAHC) | United States | $1.135B | 14.51 |
| BioLife Solutions (BLFS) | United States | $1.085B | 0.00 |
| InMode (INMD) | Israel | $0.958B | 9.66 |
| Kestra Medical Technologies (KMTS) | United States | $0.805B | 0.00 |
| Owens & Minor (OMI) | United States | $0.712B | 5.90 |
| CeriBell (CBLL) | United States | $0.684B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.680B | 0.00 |
| Evolus (EOLS) | United States | $0.598B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.555B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.542B | 0.00 |
| Valneva SE (VALN) | France | $0.494B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.468B | 0.00 |
| Surmodics (SRDX) | United States | $0.429B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.363B | 13.33 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.360B | 0.00 |
| Quanterix (QTRX) | United States | $0.349B | 0.00 |
| SNDL (SNDL) | Canada | $0.334B | 0.00 |
| Cerus (CERS) | United States | $0.294B | 0.00 |
| ZimVie (ZIMV) | United States | $0.285B | 12.98 |
| Viemed Healthcare (VMD) | United States | $0.283B | 23.83 |
| Sanuwave Health (SNWV) | United States | $0.271B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.264B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.255B | 75.67 |
| Brainsway (BWAY) | Israel | $0.250B | 66.20 |
| Cresco Labs (CRLBF) | United States | $0.246B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.235B | 0.00 |
| Biote (BTMD) | United States | $0.231B | 6.49 |
| OraSure Technologies (OSUR) | United States | $0.230B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.192B | 0.00 |
| Organigram Global (OGI) | Canada | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.190B | 15.46 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.177B | 0.00 |
| Exagen (XGN) | United States | $0.150B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.144B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.133B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.097B | 12.48 |
| MacroGenics (MGNX) | United States | $0.092B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Veru (VERU) | United States | $0.089B | 0.00 |
| Apyx Medical (APYX) | United States | $0.087B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.084B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.077B | 0.00 |
| Zynex (ZYXI) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.068B | 0.00 | |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 57.57 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.86 |
| Safety Shot (SHOT) | United States | $0.030B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.028B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.012B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |